These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 32899866)

  • 1. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
    Piezzo M; Cocco S; Caputo R; Cianniello D; Gioia GD; Lauro VD; Fusco G; Martinelli C; Nuzzo F; Pensabene M; De Laurentiis M
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
    Teh JLF; Aplin AE
    Clin Cancer Res; 2019 Feb; 25(3):921-927. PubMed ID: 30287548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
    Knudsen ES; Witkiewicz AK
    Oncotarget; 2016 Oct; 7(43):69111-69123. PubMed ID: 27564114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
    Sammons SL; Topping DL; Blackwell KL
    Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
    Corona SP; Generali D
    Drug Des Devel Ther; 2018; 12():321-330. PubMed ID: 29497278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J; Ma CX
    Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
    Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
    Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.
    Braal CL; Jongbloed EM; Wilting SM; Mathijssen RHJ; Koolen SLW; Jager A
    Drugs; 2021 Feb; 81(3):317-331. PubMed ID: 33369721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D
    Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.
    Glaviano A; Wander SA; Baird RD; Yap KC; Lam HY; Toi M; Carbone D; Geoerger B; Serra V; Jones RH; Ngeow J; Toska E; Stebbing J; Crasta K; Finn RS; Diana P; Vuina K; de Bruin RAM; Surana U; Bardia A; Kumar AP
    Drug Resist Updat; 2024 Sep; 76():101103. PubMed ID: 38943828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CDK4/6 pathways and beyond in breast cancer.
    Ribnikar D; Volovat SR; Cardoso F
    Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.
    Cetin B; Wabl CA; Gumusay O
    Future Oncol; 2022 Mar; 18(9):1143-1157. PubMed ID: 35137602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
    Spring L; Bardia A; Modi S
    Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK4-6 inhibitors in breast cancer: current status and future development.
    Choo JR; Lee SC
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.